

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/632,399	08/01/2003	James A. Thomson	960296.96536	2925	
7590 04/17/2006			EXAMINER		
Nicholas J. Seay			WOITACH, JOSEPH T		
P O Box 2113 Madison, WI 53701-2113			ART UNIT	PAPER NUMBER	
			1632	1632	
		DATE MAILED: 04/17/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/632,399	THOMSON ET AL.				
Office Action Summary	Examiner	Art Unit				
	Joseph T. Woitach	1632				
The MAILING DATE of this communication appeariod for Reply	pears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	PATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDON	DN. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 27 J	anuary 2006.					
	s action is non-final.					
· <u> </u>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11,	453 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) 16-25 is/are pending in the application	1)⊠ Claim(s) <u>16-25</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>16-25</u> is/are rejected.						
7) Claim(s) is/are objected to.	☐ Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	or election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	e Action or form PTO-152.				
Priority under 35 U.S.C. § 119		•				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1.☐ Certified copies of the priority document	ts have been received.					
3. Copies of the certified copies of the prior	rity documents have been recei	ved in this National Stage				
application from the International Burea	• • •					
* See the attached detailed Office action for a list	of the certified copies not receive	ved.				
Attachment(s)						
1) Motice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date						
Notice of Draitsperson's Fatelit Drawing Neview (FTO-946) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152) Other:						

Art Unit: 1632

DETAILED ACTION

This application filed August 1, 2003, is a continuation of 09/510,444, filed 02/21/2000, now US PAT 6,602,711.

The preliminary amendment filed August 8, 2003 has been received and entered. The specification has been amended. Claims 16-25 are pending.

Examiners' comment

As indicated in Applicants response, the restriction requirement mailed January 5, 2005, failed to consider the preliminary amendment filed August 1, 2003 with the application.

Accordingly, the restriction requirement is vacated.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Joe World

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 16-25 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 6,602,711 B1. Although the conflicting claims are not identical, they are not patentably distinct from each other because one obvious use of embryoid bodies acknowledged in the art and taught in the specification (see column 4) is for their use in studying differentiation. In this case, the instantly claimed methods and those set forth in '711 differ only in that the ES cells in the embryoid body are cultured to differentiate. The present specification provides no other uses for embyroid bodies other than for providing a product suitable for differentiation (column 3, lines 35-42).

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Woitach whose telephone number is (571) 272-0739.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached at (571) 272-0735.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group analyst Dianiece Jacobs whose telephone number is (571) 272-0532.

Joseph T. Woitach